[
  {
    "title": "AbbVie's Options Frenzy: What You Need to Know",
    "published": 1713184680,
    "posting_price": 160.22003612,
    "close_price": 157.44451904,
    "percent_change": -1.73231585
  },
  {
    "title": "Roche reports survival data for new dual-acting lymphoma drug",
    "published": 1713182220,
    "posting_price": 160.22003612,
    "close_price": 157.44451904,
    "percent_change": -1.73231585
  },
  {
    "title": "AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant for Preventive Treatment of Migraine",
    "published": 1713176025,
    "posting_price": 160.22003612,
    "close_price": 157.44451904,
    "percent_change": -1.73231585
  },
  {
    "title": "See Which Of The Latest 13F Filers Holds AbbVie",
    "published": 1713168360,
    "posting_price": 160.22003612,
    "close_price": 157.44451904,
    "percent_change": -1.73231585
  },
  {
    "title": "Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug",
    "published": 1713158409,
    "posting_price": 160.22003612,
    "close_price": 157.44451904,
    "percent_change": -1.73231585
  },
  {
    "title": "AbbVie Stock (NYSE:ABBV): Humira Leads Market with 96% Share",
    "published": 1713144660,
    "posting_price": 160.22003612,
    "close_price": 157.44451904,
    "percent_change": -1.73231585
  },
  {
    "title": "AbbVie: Great To Be Proven Wrong - Still Not A Buy",
    "published": 1713088800,
    "posting_price": 160.22003612,
    "close_price": 157.44451904,
    "percent_change": -1.73231585
  },
  {
    "title": "BME: Discount Widens Substantially Creating An Opportunity",
    "published": 1713085944,
    "posting_price": 160.22003612,
    "close_price": 157.44451904,
    "percent_change": -1.73231585
  },
  {
    "title": "Is AbbVie a Millionaire Maker?",
    "published": 1713072180,
    "posting_price": 160.22003612,
    "close_price": 157.44451904,
    "percent_change": -1.73231585
  },
  {
    "title": "AbbVie keeps Humira market share near 100% despite biosimilars: report",
    "published": 1713002160,
    "posting_price": 160.22003612,
    "close_price": 157.44451904,
    "percent_change": -1.73231585
  },
  {
    "title": "What's Going On AbbVie Stock On Friday?",
    "published": 1712953194,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors",
    "published": 1712937726,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "AbbVie: Bulletproof Fundamentals",
    "published": 1712931054,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors",
    "published": 1712930046,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%",
    "published": 1712921755,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA\u00ae) for Preventive Treatment of Migraine",
    "published": 1712921400,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "GLP-1s benefit Parkinson\u2019s: Barclays sees implications across biopharma",
    "published": 1712919780,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "AbbVie Enters Oversold Territory",
    "published": 1712918280,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "AbbVie hails positive results for chronic migraine prevention",
    "published": 1712913900,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "Smart Money Is Betting Big In ABBV Options",
    "published": 1712913000,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "Biogen Is Suffering From Doubts About the Future",
    "published": 1712908860,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "Here It Is! My 20-Stock 6-Figure Market-Beating Dividend Portfolio",
    "published": 1712905200,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "AbbVie presents results from ongoing Phase 3 study of oral atogepant",
    "published": 1712903580,
    "posting_price": 160.15185632,
    "close_price": 158.03857422,
    "percent_change": -1.31954893
  },
  {
    "title": "AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors",
    "published": 1712871919,
    "posting_price": 163.25305589,
    "close_price": 161.6321106,
    "percent_change": -0.99290349
  },
  {
    "title": "Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024",
    "published": 1712855422,
    "posting_price": 163.25305589,
    "close_price": 161.6321106,
    "percent_change": -0.99290349
  },
  {
    "title": "What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences",
    "published": 1712849028,
    "posting_price": 163.25305589,
    "close_price": 161.6321106,
    "percent_change": -0.99290349
  },
  {
    "title": "AbbVie Inc's Dividend Analysis",
    "published": 1712833335,
    "posting_price": 163.25305589,
    "close_price": 161.6321106,
    "percent_change": -0.99290349
  },
  {
    "title": "May 31st Options Now Available For AbbVie (ABBV)",
    "published": 1712830680,
    "posting_price": 163.25305589,
    "close_price": 161.6321106,
    "percent_change": -0.99290349
  },
  {
    "title": "The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today",
    "published": 1712825520,
    "posting_price": 163.25305589,
    "close_price": 161.6321106,
    "percent_change": -0.99290349
  },
  {
    "title": "Alkermes' Innovations Are Transforming Mental Health Treatments",
    "published": 1712822460,
    "posting_price": 163.25305589,
    "close_price": 161.6321106,
    "percent_change": -0.99290349
  },
  {
    "title": "Are You Looking for a High-Growth Dividend Stock?",
    "published": 1712763907,
    "posting_price": 162.66451275,
    "close_price": 163.08905029,
    "percent_change": 0.26098965
  },
  {
    "title": "AbbVie Is \u2018One of the Best Positioned\u2019 Large Cap Stocks",
    "published": 1712760780,
    "posting_price": 162.66451275,
    "close_price": 163.08905029,
    "percent_change": 0.26098965
  },
  {
    "title": "The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors",
    "published": 1712760365,
    "posting_price": 162.66451275,
    "close_price": 163.08905029,
    "percent_change": 0.26098965
  },
  {
    "title": "Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML",
    "published": 1712756940,
    "posting_price": 162.66451275,
    "close_price": 163.08905029,
    "percent_change": 0.26098965
  },
  {
    "title": "The Zacks Analyst Blog Highlights AbbVie, Salesforce, General Electric, The TJX Companies and UBS Group",
    "published": 1712754180,
    "posting_price": 162.66451275,
    "close_price": 163.08905029,
    "percent_change": 0.26098965
  },
  {
    "title": "Buy Rating on AbbVie: Resilient Humira Market Position and Promising Pipeline Outlook",
    "published": 1712733960,
    "posting_price": 162.66451275,
    "close_price": 163.08905029,
    "percent_change": 0.26098965
  },
  {
    "title": "AbbVie pullback brings attractive entry point, says JPMorgan",
    "published": 1712729160,
    "posting_price": 162.66451275,
    "close_price": 163.08905029,
    "percent_change": 0.26098965
  },
  {
    "title": "Analysts Conflicted on These Healthcare Names: Conmed (CNMD), AbbVie (ABBV) and Nurix Therapeutics (NRIX)",
    "published": 1712722260,
    "posting_price": 162.66451275,
    "close_price": 163.08905029,
    "percent_change": 0.26098965
  },
  {
    "title": "Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says",
    "published": 1712715720,
    "posting_price": 162.66451275,
    "close_price": 163.08905029,
    "percent_change": 0.26098965
  },
  {
    "title": "Top Stock Reports for AbbVie, Salesforce & General Electric",
    "published": 1712688240,
    "posting_price": 163.76444105,
    "close_price": 164.16003418,
    "percent_change": 0.24156229
  },
  {
    "title": "SkinMedica\u00ae Empowers Clear Skin Confidence with a New, Modern Approach to Acne",
    "published": 1712664000,
    "posting_price": 163.76444105,
    "close_price": 164.16003418,
    "percent_change": 0.24156229
  },
  {
    "title": "10 Unstoppable Dividend Stocks To Buy",
    "published": 1712661183,
    "posting_price": 163.76444105,
    "close_price": 164.16003418,
    "percent_change": 0.24156229
  },
  {
    "title": "Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?",
    "published": 1712658005,
    "posting_price": 163.76444105,
    "close_price": 164.16003418,
    "percent_change": 0.24156229
  },
  {
    "title": "Syros jumps on FDA fast track tag for leukemia drug",
    "published": 1712657220,
    "posting_price": 163.76444105,
    "close_price": 164.16003418,
    "percent_change": 0.24156229
  },
  {
    "title": "3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade",
    "published": 1712650860,
    "posting_price": 163.76444105,
    "close_price": 164.16003418,
    "percent_change": 0.24156229
  },
  {
    "title": "Here's Why AbbVie (ABBV) Fell More Than Broader Market",
    "published": 1712613019,
    "posting_price": 163.26274114,
    "close_price": 163.83200073,
    "percent_change": 0.34867698
  },
  {
    "title": "AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision",
    "published": 1712575516,
    "posting_price": 163.26274114,
    "close_price": 163.83200073,
    "percent_change": 0.34867698
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM)",
    "published": 1712544600,
    "posting_price": 163.26274114,
    "close_price": 163.83200073,
    "percent_change": 0.34867698
  },
  {
    "title": "Analysts Conflicted on These Healthcare Names: AbbVie (ABBV), Universal Health (UHS) and Teladoc (TDOC)",
    "published": 1712543520,
    "posting_price": 163.26274114,
    "close_price": 163.83200073,
    "percent_change": 0.34867698
  },
  {
    "title": "Morgan Stanley sees Fed rate cut fueling biotech stocks",
    "published": 1712493540,
    "posting_price": 163.26272593,
    "close_price": 163.83198547,
    "percent_change": 0.34867698
  },
  {
    "title": "Morgan Stanley sees Fed rate cut fueling biotech stock performance",
    "published": 1712493180,
    "posting_price": 163.26272593,
    "close_price": 163.83198547,
    "percent_change": 0.34867698
  },
  {
    "title": "Do These 3 Checks Before Buying AbbVie Inc. (NYSE:ABBV) For Its Upcoming Dividend",
    "published": 1712493127,
    "posting_price": 163.26272593,
    "close_price": 163.83198547,
    "percent_change": 0.34867698
  },
  {
    "title": "3 No-Brainer Dividend Stocks to Buy in April",
    "published": 1712400540,
    "posting_price": 163.26272593,
    "close_price": 163.83198547,
    "percent_change": 0.34867698
  },
  {
    "title": "Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why",
    "published": 1712399820,
    "posting_price": 163.26272593,
    "close_price": 163.83198547,
    "percent_change": 0.34867698
  },
  {
    "title": "Dividend Champion, Contender, And Challenger Highlights: Week Of April 7",
    "published": 1712394285,
    "posting_price": 163.26272593,
    "close_price": 163.83198547,
    "percent_change": 0.34867698
  },
  {
    "title": "CollPlant Biotechnologies Ltd (CLGN) Q4 2023 Earnings Call Transcript Highlights: A Year of ...",
    "published": 1712353501,
    "posting_price": 162.09525793,
    "close_price": 164.02496338,
    "percent_change": 1.19047619
  },
  {
    "title": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It",
    "published": 1712322016,
    "posting_price": 162.09525793,
    "close_price": 164.02496338,
    "percent_change": 1.19047619
  },
  {
    "title": "AbbVie (NYSE:ABBV) Trims EPS Outlook, Stock Drops",
    "published": 1712320620,
    "posting_price": 162.09525793,
    "close_price": 164.02496338,
    "percent_change": 1.19047619
  },
  {
    "title": "Boehringer Ingelheim to lay off staff amid biosimilar challenges",
    "published": 1712318400,
    "posting_price": 162.09525793,
    "close_price": 164.02496338,
    "percent_change": 1.19047619
  },
  {
    "title": "BME: Trading At A Historical Discount To NAV",
    "published": 1712317631,
    "posting_price": 162.09525793,
    "close_price": 164.02496338,
    "percent_change": 1.19047619
  },
  {
    "title": "UPDATE 1-Boehringer to lay off salespeople as Humira biosimilar sales lag",
    "published": 1712313544,
    "posting_price": 162.09525793,
    "close_price": 164.02496338,
    "percent_change": 1.19047619
  },
  {
    "title": "AbbVie\u2019s Humira outperforms forcing biosimilar maker to cut sales staff",
    "published": 1712302500,
    "posting_price": 162.09525793,
    "close_price": 164.02496338,
    "percent_change": 1.19047619
  },
  {
    "title": "Dividend Roundup: Citigroup, Mastercard, AT&T, PNC Financial, and more",
    "published": 1712300820,
    "posting_price": 162.09525793,
    "close_price": 164.02496338,
    "percent_change": 1.19047619
  },
  {
    "title": "Boehringer to lay off salespeople as Humira biosimilar sales lag",
    "published": 1712299144,
    "posting_price": 162.09525793,
    "close_price": 164.02496338,
    "percent_change": 1.19047619
  },
  {
    "title": "AbbVie Unusual Options Activity For April 05",
    "published": 1712287200,
    "posting_price": 162.09525793,
    "close_price": 164.02496338,
    "percent_change": 1.19047619
  },
  {
    "title": "Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year",
    "published": 1712237312,
    "posting_price": 171.40607796,
    "close_price": 161.99876404,
    "percent_change": -5.48831992
  },
  {
    "title": "AbbVie to Host First-Quarter 2024 Earnings Conference Call",
    "published": 1712232000,
    "posting_price": 171.40607796,
    "close_price": 161.99876404,
    "percent_change": -5.48831992
  },
  {
    "title": "May 24th Options Now Available For AbbVie",
    "published": 1712223840,
    "posting_price": 171.40607796,
    "close_price": 161.99876404,
    "percent_change": -5.48831992
  },
  {
    "title": "Aldeyra gains as Perceptive Advisors boosts stake",
    "published": 1712222460,
    "posting_price": 171.40607796,
    "close_price": 161.99876404,
    "percent_change": -5.48831992
  },
  {
    "title": "Market Today: Meta Platforms Hits Record High Amid AI Optimism, AbbVie Adjusts Guidance",
    "published": 1712205660,
    "posting_price": 171.40607796,
    "close_price": 161.99876404,
    "percent_change": -5.48831992
  },
  {
    "title": "AbbVie slips after revising guidance to reflect earnings impact",
    "published": 1712196900,
    "posting_price": 171.40607796,
    "close_price": 161.99876404,
    "percent_change": -5.48831992
  },
  {
    "title": "AbbVie : Results of Operations and Financial Condition - Form 8-K",
    "published": 1712160498,
    "posting_price": 174.36820152,
    "close_price": 171.09735107,
    "percent_change": -1.87582966
  },
  {
    "title": "10 Health Care Stocks Whale Activity In Today's Session",
    "published": 1712148060,
    "posting_price": 174.36820152,
    "close_price": 171.09735107,
    "percent_change": -1.87582966
  },
  {
    "title": "2 Strong Dividend Buys And 2 Sells For Q2 2024",
    "published": 1712139180,
    "posting_price": 174.36820152,
    "close_price": 171.09735107,
    "percent_change": -1.87582966
  },
  {
    "title": "Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting\u00ae",
    "published": 1712133071,
    "posting_price": 174.36820152,
    "close_price": 171.09735107,
    "percent_change": -1.87582966
  },
  {
    "title": "Aldeyra gains as Oppenheimer upgrades on revised plans for lead asset",
    "published": 1712131620,
    "posting_price": 174.36820152,
    "close_price": 171.09735107,
    "percent_change": -1.87582966
  },
  {
    "title": "Vertex Is Worth Your Attention",
    "published": 1712131260,
    "posting_price": 174.36820152,
    "close_price": 171.09735107,
    "percent_change": -1.87582966
  },
  {
    "title": "Oppenheimer more bullish on Aldeyra, upgrades to Outperform",
    "published": 1712125680,
    "posting_price": 174.36820152,
    "close_price": 171.09735107,
    "percent_change": -1.87582966
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and AbbVie (ABBV)",
    "published": 1712118060,
    "posting_price": 174.36820152,
    "close_price": 171.09735107,
    "percent_change": -1.87582966
  },
  {
    "title": "The 3 Best Stocks to Buy in April 2024",
    "published": 1712085886,
    "posting_price": 173.08492197,
    "close_price": 174.3392334,
    "percent_change": 0.72467978
  },
  {
    "title": "US takes next step in Medicare drug price negotiations with pharma companies",
    "published": 1712076118,
    "posting_price": 173.08492197,
    "close_price": 174.3392334,
    "percent_change": 0.72467978
  },
  {
    "title": "NEXGEL, Inc. (NASDAQ:NXGL) Q4 2023 Earnings Call Transcript",
    "published": 1712068948,
    "posting_price": 173.08492197,
    "close_price": 174.3392334,
    "percent_change": 0.72467978
  },
  {
    "title": "AbbVie put volume heavy and directionally bearish",
    "published": 1712052960,
    "posting_price": 173.08492197,
    "close_price": 174.3392334,
    "percent_change": 0.72467978
  },
  {
    "title": "Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation",
    "published": 1712043360,
    "posting_price": 173.08492197,
    "close_price": 174.3392334,
    "percent_change": 0.72467978
  },
  {
    "title": "AbbVie Inc: An Exploration into Its Intrinsic Value",
    "published": 1712037660,
    "posting_price": 173.08492197,
    "close_price": 174.3392334,
    "percent_change": 0.72467978
  },
  {
    "title": "The 'Extremely Positive' Results That Helped Roivant Leapfrog Its 50-Day Line, Nearing A Breakout",
    "published": 1712034246,
    "posting_price": 173.08492197,
    "close_price": 174.3392334,
    "percent_change": 0.72467978
  },
  {
    "title": "A Deep Dive Into Investing Strategies For A Rich Retirement",
    "published": 1712029379,
    "posting_price": 173.08492197,
    "close_price": 174.3392334,
    "percent_change": 0.72467978
  },
  {
    "title": "7 Safe Haven Stocks That Can Withstand the Market\u2019s Worst Meltdowns",
    "published": 1714499457,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "Trials to watch: Four ALS drugs to keep an eye on",
    "published": 1714492970,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "AbbVie (ABBV) Could Be a Great Choice",
    "published": 1714491904,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "2 Dividend Stocks To Watch In May 2024",
    "published": 1714485560,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "published": 1714482602,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition",
    "published": 1714482180,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "AbbVie : Reinforces Commitment to Science and Innovation with a \u20ac150 million Euro Investment in New Cutting-Edge Research and Development Facility in Germany",
    "published": 1714481475,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript",
    "published": 1714480705,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "Novo, Teva, AstraZeneca issued FTC warnings over \u2018bogus\u2019 patents",
    "published": 1714476240,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "Alvotech to produce Humira biosimilar for Cigna's Quallent",
    "published": 1714474800,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing",
    "published": 1714473120,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "Earnings Beat: AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models",
    "published": 1714472504,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "AbbVie Inc: An Exploration into Its Intrinsic Value",
    "published": 1714456860,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Molina Healthcare (MOH) and Cytokinetics (CYTK)",
    "published": 1714443120,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "Hold Rating on AbbVie Amidst Humira Concerns and Biosimilar Competition Despite Strong Pipeline Prospects",
    "published": 1714439160,
    "posting_price": 157.05497191,
    "close_price": 158.38916016,
    "percent_change": 0.84950399
  },
  {
    "title": "AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales",
    "published": 1714408035,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "AbbVie: The Inevitable Is Happening",
    "published": 1714403333,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week",
    "published": 1714395360,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Peeling Back The Layers: Exploring AbbVie Through Analyst Insights",
    "published": 1714384980,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "AbbVie price target lowered by $15 at BMO Capital, here's why",
    "published": 1714380540,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Novo Nordisk: Growth Is Still A Better Choice",
    "published": 1714377660,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "AbbVie price target lowered by $5 at Morgan Stanley, here's why",
    "published": 1714377420,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Analysts\u2019 Top Healthcare Picks: AbbVie (ABBV), Wave Life Sciences (WVE)",
    "published": 1714373580,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Truist Financial Sticks to Its Buy Rating for AbbVie (ABBV)",
    "published": 1714373400,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Buy Rating Affirmed: AbbVie\u2019s Strong Performance and Positive Growth Outlook",
    "published": 1714372080,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Unveiling AbbVie's Winning Strategy In Pharmaceutical Innovation (Rating Upgrade)",
    "published": 1714370936,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Buy Rating Reaffirmed for AbbVie: Future Growth Beyond Humira\u2019s Competition",
    "published": 1714369620,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales",
    "published": 1714367175,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), OptimizeRx (OPRX) and AbbVie (ABBV)",
    "published": 1714366260,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "AbbVie price target lowered by $8 at Barclays, here's why",
    "published": 1714366080,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Dividend Stock Portfolio For Income: Top 15 Stocks",
    "published": 1714344883,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "AbbVie First Quarter 2024 Earnings: Beats Expectations",
    "published": 1714308165,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade",
    "published": 1714305840,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Better Dividend Stock: AbbVie or Johnson & Johnson?",
    "published": 1714292400,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "3 Dividend Stocks to Buy and Hold for the Next Decade",
    "published": 1714216500,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "AbbVie Inc (ABBV) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations with ...",
    "published": 1714201635,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Q1 2024 AbbVie Inc Earnings Call",
    "published": 1714195493,
    "posting_price": 155.41886718,
    "close_price": 157.2984314,
    "percent_change": 1.20935396
  },
  {
    "title": "Abbvie stock falls amid growing biosimilar competition",
    "published": 1714167097,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That",
    "published": 1714162112,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Why AbbVie Stock Stumbled Today Despite the Earnings Beat",
    "published": 1714162031,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie (ABBV) Q1 2024 Earnings Call Transcript",
    "published": 1714158913,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q",
    "published": 1714150458,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View",
    "published": 1714147800,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks",
    "published": 1714143739,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "PCE/Core PCE Numbers Came In Line With Expectations",
    "published": 1714143180,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses",
    "published": 1714141980,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say",
    "published": 1714141802,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop",
    "published": 1714139880,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie Inc. (ABBV) Q1 2024 Earnings Call Transcript",
    "published": 1714137932,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates Despite Revenue Challenges",
    "published": 1714137106,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?",
    "published": 1714135800,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates",
    "published": 1714135502,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie's Q1: Positive Surprise",
    "published": 1714132910,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie tries to reassure investors on Humira biosimilar threat",
    "published": 1714132860,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Drugmaker AbbVie expects Humira volume erosion to worsen",
    "published": 1714131871,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie raises annual profit forecast on strong Skyrizi sales",
    "published": 1714131394,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie Reports First-Quarter 2024 Financial Results",
    "published": 1714131300,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Interesting ABBV Put And Call Options For July 19th",
    "published": 1714129980,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "What You Missed On Wall Street This Morning",
    "published": 1714129440,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024",
    "published": 1714128900,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie Q1 report beats Street despite plunging Humira sales",
    "published": 1714126920,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie off 3% despite quarterly beats, 2024 guidance raise",
    "published": 1714124220,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie says Humira downdraft 'within what was assumed'",
    "published": 1714122000,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "EOI: 9% Plus Income, Paid Monthly, And Solid Past Record",
    "published": 1714122000,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook",
    "published": 1714121940,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie sees FY24 revenue approximately $55B, consensus $54.6B",
    "published": 1714120800,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie sees Q2 adjusted EPS $3.05-$3.09, consensus $2.81",
    "published": 1714120560,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie raises annual targets",
    "published": 1714120366,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises",
    "published": 1714119990,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie reports quarterly revenue rise and net earnings boost",
    "published": 1714119960,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie in charts: Q1 Skyrizi, Rinvoq sales jump, while revenue from Humira continues to fall",
    "published": 1714119300,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie says Q1 results exceeded expectations",
    "published": 1714119120,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "5 stocks to watch on Friday: XOM, CVX, ABBV and more",
    "published": 1714119000,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Fly Intel: Pre-market Movers",
    "published": 1714118040,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie: Q1 Earnings Snapshot",
    "published": 1714117450,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie\u2019s first-quarter results top expectations as arthritis drugs fuel growth",
    "published": 1714114140,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie reports Q1 global revenue from immunology portfolio $5.371B, down 3.9%",
    "published": 1714113780,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie Non-GAAP EPS of $2.31 beats by $0.05, revenue of $12.31B beats by $370M",
    "published": 1714113600,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie raises FY24 adjusted EPS view to $11.13-$11.33 from $10.97-$11.17",
    "published": 1714113420,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie reports Q1 adjusted EPS $2.31, consensus $2.23",
    "published": 1714113360,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Options Volatility and Implied Earnings Moves Today, April 26, 2024",
    "published": 1714111560,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet",
    "published": 1714110780,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie (NYSE:ABBV) Sinks as Humira Drug Sees Increased Competition",
    "published": 1714106400,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Hold Rating on AbbVie Amid Revenue Decline and Profitability Concerns",
    "published": 1714104420,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "What You Missed On Wall Street On Friday",
    "published": 1714100940,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost",
    "published": 1714095780,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "AbbVie stock slides 6% amid concerns about falling Humira sales",
    "published": 1714094040,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "More than half of the S&P 500 names that reported results this week beat top and bottom line - Earnings Scorecard",
    "published": 1714093680,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "GLOBAL BRIEFING: Yen slumps to new multi-decade low as BoJ stands pat",
    "published": 1714091700,
    "posting_price": 162.72283528,
    "close_price": 155.44807434,
    "percent_change": -4.47064539
  },
  {
    "title": "Cigna to offer Humira rivals with $0 copay at specialty pharmacy",
    "published": 1714078119,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)",
    "published": 1714067356,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "NEW YORK MARKET CLOSE: Stocks ebb on stagflation fears as growth slows",
    "published": 1714061580,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study",
    "published": 1714049044,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie",
    "published": 1714048380,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "Notable companies reporting before tomorrow's open",
    "published": 1714047060,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "New Data Show RINVOQ\u00ae (upadacitinib) Demonstrated Superiority Versus DUPIXENT\u00ae (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study",
    "published": 1714046400,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "AbbVie reports positive results from Rinvoq versus Dupixent study",
    "published": 1714041000,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "Notable earnings before Friday's open",
    "published": 1714039620,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "AbbVie Q1 Preview: Skyrizi and Rinvoq\u2019s launches could help Q1",
    "published": 1714037100,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys",
    "published": 1714032600,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "Polaris Global Equity Composite Q1 2024 Commentary",
    "published": 1714032000,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "AbbVie reports 'positive' results from LEVEL UP study",
    "published": 1714028700,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition",
    "published": 1714021560,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "AbbVie Inc. stock outperforms competitors despite losses on the day",
    "published": 1714016400,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study",
    "published": 1714006920,
    "posting_price": 163.2779421,
    "close_price": 162.91760254,
    "percent_change": -0.2206909
  },
  {
    "title": "Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?",
    "published": 1713974700,
    "posting_price": 164.11548959,
    "close_price": 163.41430664,
    "percent_change": -0.42724971
  },
  {
    "title": "4 Large Drug Stocks to Hold on to Amid Industry Challenges",
    "published": 1713967740,
    "posting_price": 164.11548959,
    "close_price": 163.41430664,
    "percent_change": -0.42724971
  },
  {
    "title": "What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?",
    "published": 1713964740,
    "posting_price": 164.11548959,
    "close_price": 163.41430664,
    "percent_change": -0.42724971
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?",
    "published": 1713954006,
    "posting_price": 164.11548959,
    "close_price": 163.41430664,
    "percent_change": -0.42724971
  },
  {
    "title": "Eaton Vance Worldwide Health Sciences Fund Bolsters Position in IDEXX Laboratories",
    "published": 1713952920,
    "posting_price": 164.11548959,
    "close_price": 163.41430664,
    "percent_change": -0.42724971
  },
  {
    "title": "Allergan Aesthetics Invites Consumers to Be the Face of BOTOX Cosmetic and Their Other Biggest Brands",
    "published": 1713948768,
    "posting_price": 164.11548959,
    "close_price": 163.41430664,
    "percent_change": -0.42724971
  },
  {
    "title": "Abbvie breaks six day winning cycle, trades in the red",
    "published": 1713929100,
    "posting_price": 164.11548959,
    "close_price": 163.41430664,
    "percent_change": -0.42724971
  },
  {
    "title": "Wall Street Analysts Are Neutral on Top Healthcare Picks",
    "published": 1713928860,
    "posting_price": 164.11548959,
    "close_price": 163.41430664,
    "percent_change": -0.42724971
  },
  {
    "title": "Nvidia will soar 21% to $1,000 as its new AI chip slams would-be rivals, Morgan Stanley says. It\u2019s among 10 stocks set to surge",
    "published": 1713899367,
    "posting_price": 164.18364308,
    "close_price": 165.10881042,
    "percent_change": 0.56349544
  },
  {
    "title": "Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth",
    "published": 1713880861,
    "posting_price": 164.18364308,
    "close_price": 165.10881042,
    "percent_change": 0.56349544
  },
  {
    "title": "Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics",
    "published": 1713878123,
    "posting_price": 164.18364308,
    "close_price": 165.10881042,
    "percent_change": 0.56349544
  },
  {
    "title": "US CDC warns of harmful reactions to fake Botox injections",
    "published": 1713874478,
    "posting_price": 164.18364308,
    "close_price": 165.10881042,
    "percent_change": 0.56349544
  },
  {
    "title": "Allergan Aesthetics Invites Consumers to Be the Face of BOTOX\u00ae Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands",
    "published": 1713873600,
    "posting_price": 164.18364308,
    "close_price": 165.10881042,
    "percent_change": 0.56349544
  },
  {
    "title": "Takeda Pharmaceutical: A Long-Term Cash Cow",
    "published": 1713859260,
    "posting_price": 164.18364308,
    "close_price": 165.10881042,
    "percent_change": 0.56349544
  },
  {
    "title": "Not A Millionaire? No Problem! Here's A 10-Stock Portfolio To Retire Comfortably",
    "published": 1713855620,
    "posting_price": 164.18364308,
    "close_price": 165.10881042,
    "percent_change": 0.56349544
  },
  {
    "title": "Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes",
    "published": 1713843840,
    "posting_price": 164.18364308,
    "close_price": 165.10881042,
    "percent_change": 0.56349544
  },
  {
    "title": "AbbVie's Options Frenzy: What You Need to Know",
    "published": 1713836880,
    "posting_price": 164.18364308,
    "close_price": 165.10881042,
    "percent_change": 0.56349544
  },
  {
    "title": "AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?",
    "published": 1713804960,
    "posting_price": 163.29743524,
    "close_price": 163.50195312,
    "percent_change": 0.12524255
  },
  {
    "title": "Buying the Dip in These 3 Undervalued Dividend Stocks",
    "published": 1713793620,
    "posting_price": 163.29743524,
    "close_price": 163.50195312,
    "percent_change": 0.12524255
  },
  {
    "title": "Dividend yield and growth stock list by Goldman",
    "published": 1713780600,
    "posting_price": 163.29743524,
    "close_price": 163.50195312,
    "percent_change": 0.12524255
  },
  {
    "title": "EU regulators approve Pfizer antibiotic Emblaveo",
    "published": 1713777480,
    "posting_price": 163.29743524,
    "close_price": 163.50195312,
    "percent_change": 0.12524255
  },
  {
    "title": "AbbVie (ABBV) Gets a Buy from Piper Sandler",
    "published": 1713770880,
    "posting_price": 163.29743524,
    "close_price": 163.50195312,
    "percent_change": 0.12524255
  },
  {
    "title": "3 Dividend Kings Down 11% You\u2019ll Regret Not Buying on the Dip",
    "published": 1713769440,
    "posting_price": 163.29743524,
    "close_price": 163.50195312,
    "percent_change": 0.12524255
  },
  {
    "title": "Options Volatility and Implied Earnings Moves This Week, April 22 \u2013 April 26, 2024",
    "published": 1713765720,
    "posting_price": 163.29743524,
    "close_price": 163.50195312,
    "percent_change": 0.12524255
  },
  {
    "title": "Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more",
    "published": 1713683100,
    "posting_price": 163.29743524,
    "close_price": 163.50195312,
    "percent_change": 0.12524255
  },
  {
    "title": "Wall Street Breakfast: The Week Ahead",
    "published": 1713682002,
    "posting_price": 163.29743524,
    "close_price": 163.50195312,
    "percent_change": 0.12524255
  },
  {
    "title": "Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week",
    "published": 1713674940,
    "posting_price": 163.29743524,
    "close_price": 163.50195312,
    "percent_change": 0.12524255
  },
  {
    "title": "THQ: Collecting A High Yield From Increased Medical Spending",
    "published": 1713614580,
    "posting_price": 163.29742,
    "close_price": 163.50193787,
    "percent_change": 0.12524256
  },
  {
    "title": "20 Years To $300k? Building A $10,000 Dividend Portfolio From Scratch",
    "published": 1713596400,
    "posting_price": 163.29742,
    "close_price": 163.50193787,
    "percent_change": 0.12524256
  },
  {
    "title": "These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?",
    "published": 1713551420,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "The Bad News Heading Into AbbVie's First-Quarter Earnings Report",
    "published": 1713544997,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline",
    "published": 1713535223,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data",
    "published": 1713532500,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "AbbVie - Phase 3 SELECT-GCA Study of Upadacitinib showed Positive Results in Patients with Giant Cell Arteritis",
    "published": 1713518524,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth",
    "published": 1713510228,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "Alvotech/Teva bring new partner to expand access for Humira biosimilar in U.S.",
    "published": 1713507900,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S.",
    "published": 1713506400,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "Market Correction Expected: 20 Stocks To Buy If It Worsens",
    "published": 1713505241,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV)",
    "published": 1713501960,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "At least 70% of the S&P 500 names that reported results this week topped estimates - Earnings Scorecard",
    "published": 1713493500,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "Catalyst Watch: Tesla, Boeing and General Motors brace for earnings fireworks",
    "published": 1713492120,
    "posting_price": 160.70695354,
    "close_price": 162.06062317,
    "percent_change": 0.84232175
  },
  {
    "title": "Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study",
    "published": 1713469449,
    "posting_price": 160.64853104,
    "close_price": 160.35636902,
    "percent_change": -0.18186411
  },
  {
    "title": "Heard on the Street: AbbVie\u2019s Bet on a Neuroscience Drug Maker Just Got Better",
    "published": 1713457080,
    "posting_price": 160.64853104,
    "close_price": 160.35636902,
    "percent_change": -0.18186411
  },
  {
    "title": "AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment",
    "published": 1713447998,
    "posting_price": 160.64853104,
    "close_price": 160.35636902,
    "percent_change": -0.18186411
  },
  {
    "title": "Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ\u00ae) Showed Positive Results in Patients With Giant Cell Arteritis",
    "published": 1713443460,
    "posting_price": 160.64853104,
    "close_price": 160.35636902,
    "percent_change": -0.18186411
  },
  {
    "title": "Cerevel, in \u2018major surprise,\u2019 finds success in late-stage Parkinson\u2019s study",
    "published": 1713436200,
    "posting_price": 160.64853104,
    "close_price": 160.35636902,
    "percent_change": -0.18186411
  },
  {
    "title": "AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint",
    "published": 1713432449,
    "posting_price": 160.64853104,
    "close_price": 160.35636902,
    "percent_change": -0.18186411
  },
  {
    "title": "AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition",
    "published": 1713429240,
    "posting_price": 160.64853104,
    "close_price": 160.35636902,
    "percent_change": -0.18186411
  },
  {
    "title": "AbbVie reports 'positive' results from Phase 3 SELECT-GCA study of upadacitinib",
    "published": 1713425640,
    "posting_price": 160.64853104,
    "close_price": 160.35636902,
    "percent_change": -0.18186411
  },
  {
    "title": "Johnson & Johnson: Buy This Bargain Before It's Gone",
    "published": 1713425319,
    "posting_price": 160.64853104,
    "close_price": 160.35636902,
    "percent_change": -0.18186411
  },
  {
    "title": "AbbVie buyout Cerevel posts late-stage win for Parkinson\u2019s disease drug",
    "published": 1713420360,
    "posting_price": 160.64853104,
    "close_price": 160.35636902,
    "percent_change": -0.18186411
  },
  {
    "title": "AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know",
    "published": 1713390317,
    "posting_price": 159.85968473,
    "close_price": 159.95707703,
    "percent_change": 0.06092362
  },
  {
    "title": "CVS favors Humira copycats hurting AbbVie\u2019s market share: Evercore",
    "published": 1713342720,
    "posting_price": 159.85968473,
    "close_price": 159.95707703,
    "percent_change": 0.06092362
  },
  {
    "title": "ClearBridge Multi Cap Growth Strategy Q1 2024 Portfolio Manager Commentary",
    "published": 1713340800,
    "posting_price": 159.85968473,
    "close_price": 159.95707703,
    "percent_change": 0.06092362
  },
  {
    "title": "AbbVie (ABBV) Gets a Buy from Barclays",
    "published": 1713320760,
    "posting_price": 159.85968473,
    "close_price": 159.95707703,
    "percent_change": 0.06092362
  },
  {
    "title": "Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions",
    "published": 1713318420,
    "posting_price": 159.85968473,
    "close_price": 159.95707703,
    "percent_change": 0.06092362
  },
  {
    "title": "14 companies with a near-term catalyst around 1Q earnings - MS",
    "published": 1713317940,
    "posting_price": 159.85968473,
    "close_price": 159.95707703,
    "percent_change": 0.06092362
  },
  {
    "title": "$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today",
    "published": 1713315780,
    "posting_price": 159.85968473,
    "close_price": 159.95707703,
    "percent_change": 0.06092362
  },
  {
    "title": "Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now",
    "published": 1713293776,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "FHLC: Healthcare Dashboard For April",
    "published": 1713284682,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "AbbVie: Through Humira's Crisis Towards Solid Growth",
    "published": 1713283554,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "UPDATE 1-US FDA warns of harmful reactions to fake Botox injections",
    "published": 1713277293,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
    "published": 1713272417,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "AbbVie to develop long-acting injectables in a deal worth up to $1.9B",
    "published": 1713269220,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "AbbVie to develop long acting injectables in a deal worth up to $1.9B",
    "published": 1713268620,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "Johnson & Johnson (JNJ) Q1 Earnings Top Estimates",
    "published": 1713267002,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "Genmab Acquires A Missing Piece For Its Pipeline",
    "published": 1713266438,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "AbbVie working with FDA after reports of fake Botox versions",
    "published": 1713261000,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "12 Best Dividend Stocks with High Upside Potential",
    "published": 1713250936,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "Powell And The Great Indecision",
    "published": 1713250500,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "Invest with Confidence: Intrinsic Value Unveiled of AbbVie Inc",
    "published": 1713247260,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  },
  {
    "title": "Fake Botox Fight Sends AbbVie (NASDAQ:ABBV) Up Fractionally",
    "published": 1713229320,
    "posting_price": 157.94117186,
    "close_price": 158.29176331,
    "percent_change": 0.22197597
  }
]